Top

Published in:

01-08-2014

BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure

Authors: Mark Oremus, Andrew Don-Wauchope, Robert McKelvie, Pasqualina L. Santaguida, Stephen Hill, Cynthia Balion, Ronald Booth, Judy A. Brown, Usman Ali, Amy Bustamam, Nazmul Sohel, Parminder Raina

Published in: Heart Failure Reviews | Issue 4/2014

Abstract

Prognosis permits clinicians to separate persons with heart failure (HF) into subgroups based on likely health outcomes. Treatment is partly guided by these likely outcomes. This systematic review explores whether brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are independent predictors of prognosis in persons with chronic stable HF. We electronically searched Medline, Embase, AMED, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL for English-language articles published between 1989 and mid-2012. We utilized trained reviewers and standardized forms to screen articles for inclusion and extracted data from included articles. All included studies were summarized in narrative and tabular form. We used the Hayden criteria to assess the risk of bias. Sixteen BNP publications and 88 NT-proBNP publications were included in the systematic review. BNP was positively associated with all-cause and HF mortality. NT-proBNP was positively associated with all-cause and cardiovascular mortality. BNP and NT-proBNP levels are useful for estimating prognosis in persons with chronic stable HF. Further research is required to establish optimal cutpoints and to assess whether prognostic effects differ by age, sex, or time period.

National Clinical Guideline Centre (2010) Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. NICE clinical guideline 108. National Institute for Health and Clinical Excellence, Manchester. http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf

McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A et al (2013) The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol 29:168–181. doi:10.1016/j.cjca.2012.10.007 PubMed

McMurray JJV, Adamopoulos C, Anker S, Auricchio A (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 33:1787–1847PubMed

Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D et al (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circ Cardiovasc Qual Outcomes 120:2177–2187. doi:10.1161/CIRCULATIONAHA.109.884866

Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330:625. doi:10.1136/bmj.330.7492.62 PubMedCentralPubMed

Vesbianu D, Vesbianu C, Bernstein P, Kouides R (2008) Plasma brain natriuretic peptide—an independent predictor of mortality and rehospitalization in congestive heart failure—a meta-analysis. World Heart J 1:349–354

Oremus M, Raina PS, Santaguida P, Balion CM, McQueen MJ, McKelvie R et al (2008) A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. Clin Biochem 41:260–265. doi:10.1016/j.clinbiochem.2007.09.011 PubMed

Balion C, Santaguida PL, Hill S, Worster A, McQueen M, Oremus M, McKelvie R, Booker L, Fagbemi J, Reichert S, Raina P (2006) Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. AHRQ publication no. 06-E014. AHRQ, Rockville

Hayden JA, Côté P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427–437. doi:10.7326/0003-4819-144-6-200603210-00010 PubMed

10.

Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B (2003) Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circ Cardiovasc Qual Outcomes 107:1764–1769. doi:10.1161/01.cir.0000057980.84624.95

11.

Horwich TB, Hamilton MA, Fonarow GC (2006) B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47:85–90. doi:10.1016/j.jacc.2005.08.050 PubMed

12.

Ralli S, Horwich TB, Fonarow GC (2005) Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 150:1220–1227. doi:10.1016/j.ahj.2005.01.049 PubMed

13.

Meyer B, Mörtl D, Strecker K, Hülsmann M, Kulemann V, Neunteufl T et al (2005) Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 46:1011–1018. doi:10.1016/j.jacc.2005.04.060 PubMed

14.

Krüger S, Graf J, Merx MW, Stickel T, Kunz D, Koch KC et al (2006) The value of cardiopulmonary exercise testing and brain natriuretic peptide plasma levels in predicting the prognosis of patients with chronic heart failure. Eur J Intern Med 17:96–101. doi:10.1016/j.ejim.2005.11.001 PubMed

15.

Kozdag G, Ertas G, Kilic T, Acar E, Sahin T, Ural D (2010) Triiodothyronine and brain natriuretic peptide: similar long-term prognostic values for chronic heart failure. Tex Heart Inst J 37:538–546PubMedCentralPubMed

16.

Dries DL, Ky B, Wu AH, Rame JE, Putt ME, Cappola TP (2010) Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. Circ Heart Fail 3:220–227. doi:10.1161/CIRCHEARTFAILURE.109.903153 PubMed

17.

Boffa GM, Zaninotto M, Sartor R, Mion M, Berton A, Pasqualetto C et al (2009) Interleukin-6 and tumor necrosis factor-alpha as biochemical markers of heart failure: a head-to-head clinical comparison with B-type natriuretic peptide. J Cardiovasc Med (Hagerstown) 10:758–764. doi:10.2459/JCM.0b013e32832ce8e2

18.

Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG et al (2009) Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 53:1783–1790. doi:10.1016/j.jacc.2009.01.057 PubMed

19.

Adlbrecht C, Hulsmann M, Strunk G, Berger R, Mortl D, Struck J et al (2009) Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 11:361–366. doi:10.1093/eurjhf/hfp004 PubMed

20.

Scardovi AB, De Maria R, Celestini A, Coletta C, Aspromonte N, Perna S et al (2008) Prognostic value of brain natriuretic peptide and enhanced ventilatory response to exercise in patients with chronic heart failure. Intern Emerg Med 3:331–337. doi:10.1007/s11739-008-0163-x PubMed

21.

Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG et al (2008) Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 52:266–272. doi:10.1016/j.jacc.2008.03.050 PubMed

22.

Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT et al (2008) Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 14:140–144. doi:10.1016/j.cardfail.2007.10.013 PubMed

23.

Popescu BA, Popescu AC, Antonini-Canterin F, Rubin D, Cappelletti P, Piazza R et al (2007) Prognostic role of left atrial volume in elderly patients with symptomatic stable chronic heart failure: comparison with left ventricular diastolic dysfunction and B-type natriuretic peptide. Echocardiography 24:1035–1043. doi:10.1111/j.1540-8175.2007.00540.x PubMed

24.

Scardovi AB, De Maria R, Coletta C, Aspromonte N, Perna S, Cacciatore G et al (2007) Multiparametric risk stratification in patients with mild to moderate chronic heart failure. J Card Fail 13:445–451. doi:10.1016/j.cardfail.2007.03.003 PubMed

25.

Bermingham M, O’Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K et al (2011) Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 13:885–891. doi:10.1093/eurjhf/hfr063 PubMed

26.

Rothenburger M, Wichter T, Schmid C, Stypmann J, Tjan TD, Berendes E et al (2004) Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant 23:1189–1197. doi:10.1016/j.healun.2004.07.006 PubMed

27.

Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA (2003) N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24:1735–1743. doi:10.1016/j.ehj.2003.07.005 PubMed

28.

Gardner RS, Chong V, Morton I, McDonagh TA (2005) N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur J Heart Fail 7:253–260. doi:10.1016/j.ejheart.2004.06.002 PubMed

29.

Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P et al (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circ Cardiovasc Qual Outcomes 110:1780–1786. doi:10.1161/01.CIR.0000143059.68996.A7

30.

Corell P, Gustafsson F, Kistorp C, Madsen LH, Schou M, Hildebrandt P (2007) Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol 117:395–402. doi:10.1016/j.ijcard.2006.03.084 PubMed

31.

Schou M, Gustafsson F, Corell P, Kistorp CN, Kjaer A, Hildebrandt PR (2007) The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J 154:123–129. doi:10.1016/j.ahj.2007.04.002 PubMed

32.

Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G et al (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circ Heart Fail 115:1754–1761. doi:10.1161/CIRCULATIONAHA.106.653964

33.

Mikkelsen KV, Møller JE, Bie P, Ryde H, Videbaek L, Haghfelt T (2006) Tei index and neurohormonal activation in patients with incident heart failure: serial changes and prognostic value. Eur J Heart Fail 8:599–608. doi:10.1016/j.ejheart.2005.11.015 PubMed

34.

Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M et al (2006) Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circ Cardiovasc Qual Outcomes 114:1829–1837. doi:10.1161/CIRCULATIONAHA.106.649426

35.

Bruch C, Reinecke H, Stypmann J, Rothenburger M, Schmid C, Breithardt G et al (2006) N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure. J Heart Lung Transplant 25:1135–1141. doi:10.1016/j.healun.2006.05.006 PubMed

36.

Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S et al (2006) Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 52:1528–1538. doi:10.1373/clinchem.2006.069575 PubMed

37.

Bruch C, Rothenburger M, Gotzmann M, Sindermann J, Scheld HH, Breithardt G et al (2006) Risk stratification in chronic heart failure: independent and incremental prognostic value of echocardiography and brain natriuretic peptide and its N-terminal fragment. J Am Soc Echocardiogr 19:522–528. doi:10.1016/j.echo.2005.12.027 PubMed

38.

Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A et al (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circ Cardiovasc Qual Outcomes 112:1756–1762. doi:10.1161/CIRCULATIONAHA.104.530972

39.

George J, Patal S, Wexler D, Roth A, Sheps D, Keren G (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150:484–487. doi:10.1016/j.ahj.2004.11.016 PubMed

40.

George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T et al (2005) Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165:1304–1309. doi:10.1001/archinte.165.11.1304 PubMed

41.

Gardner RS, Chong KS, Morton JJ, McDonagh TA (2005) N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. J Card Fail 11:S47–S53. doi:10.1016/j.cardfail.2005.04.008 PubMed

42.

Gardner RS, Henderson G, McDonagh TA (2005) The prognostic use of right heart catheterization data in patients with advanced heart failure: how relevant are invasive procedures in the risk stratification of advanced heart failure in the era of neurohormones? J Heart Lung Transplant 24:303–309. doi:10.1016/j.healun.2004.01.010 PubMed

43.

Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O’Connor CM, Adams KF Jr et al (2007) Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 167:367–373. doi:10.1001/archinte.167.4.367 PubMed

44.

Jankowska EA, Drohomirecka A, Ponikowska B, Witkowska A, Lopuszanska M, Szklarska A et al (2010) Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. Eur J Heart Fail 12:966–973. doi:10.1093/eurjhf/hfq108 PubMed

45.

Codognotto M, Piccoli A, Zaninotto M, Mion MM, Ruzza L, Barchita A et al (2010) Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. J Nephrol 23:465–471PubMed

46.

Dini FL, Gabutti A, Passino C, Fontanive P, Emdin M, De Tommasi SM (2010) Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure. Int J Cardiol 140:344–350. doi:10.1016/j.ijcard.2008.11.108 PubMed

47.

Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S et al (2010) N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55:645–653. doi:10.1016/j.jacc.2009.08.078 PubMed

48.

Tsutamoto T, Kawahara C, Nishiyama K, Yamaji M, Fujii M, Yamamoto T et al (2010) Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. Am Heart J 159:63–67. doi:10.1016/j.ahj.2009.10.022 PubMed

49.

Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M et al (2009) Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure—special reference to transcardiac gradient of norepinephrine. Circ J 73:2270–2275. doi:10.1253/circj.CJ-09-0456 PubMed

50.

Al-Najjar Y, Goode KM, Zhang J, Cleland JG, Clark AL (2009) Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. Eur J Heart Fail 11:1155–1162. doi:10.1093/eurjhf/hfp147 PubMed

51.

Frankenstein L, Zugck C, Nelles M, Schellberg D, Katus HA, Remppis BA (2009) The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders. Eur J Heart Fail 11:1189–1194. doi:10.1093/eurjhf/hfp150 PubMed

52.

Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C et al (2009) Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54:1850–1859. doi:10.1016/j.jacc.2009.06.041 PubMed

53.

Charach G, George J, Afek A, Wexler D, Sheps D, Keren G et al (2009) Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure. J Card Fail 15:770–774. doi:10.1016/j.cardfail.2009.05.009 PubMed

54.

Zielinski T, Browarek A, Zembala M, Sadowski J, Zakliczynski M, Przybylowski P et al (2009) Risk stratification of patients with severe heart failure awaiting heart transplantation—Prospective National Registry POLKARD HF. Transplant Proc 41:3161–3165. doi:10.1016/j.transproceed.2009.09.049 PubMed

55.

Poletti R, Passino C, Giannoni A, Zyw L, Prontera C, Bramanti F et al (2009) Risk factors and prognostic value of daytime Cheyne–Stokes respiration in chronic heart failure patients. Int J Cardiol 137:47–53. doi:10.1016/j.ijcard.2008.06.028 PubMed

56.

Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL et al (2009) Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15:565–571. doi:10.1016/j.cardfail.2009.01.014 PubMedCentralPubMed

57.

Dini FL, Fontanive P, Buralli S, Panicucci E, Andreini D, Conti U et al (2009) N-terminal protype-B natriuretic peptide and Doppler diastolic variables are incremental for risk stratification of patients with NYHA class I-II systolic heart failure. Int J Cardiol 136:144–150. doi:10.1016/j.ijcard.2008.04.032 PubMed

58.

Vazquez R, Bayes-Genis A, Cygankiewicz I, Pascual-Figal D, Grigorian-Shamagian L, Pavon R et al (2009) The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 30:1088–1096. doi:10.1093/eurheartj/ehp032 PubMed

59.

Frankenstein L, Clark AL, Goode K, Ingle L, Remppis A, Schellberg D et al (2009) The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age. Heart 95:825–829. doi:10.1136/hrt.2008.158626 PubMed

60.

Kubánek M, Goode KM, Lánská V, Clark AL, Cleland JG (2009) The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 11:367–377. doi:10.1093/eurjhf/hfp003 PubMed

61.

Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH et al (2009) Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 11:281–291. doi:10.1093/eurjhf/hfn046 PubMedCentralPubMed

62.

Koç M, Bozkurt A, Yildiray-Sahin D, Unal I, Acartürk E (2009) Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure. Cardiol J 16:43–49PubMed

63.

Michowitz Y, Kisil S, Guzner-Gur H, Rubinstein A, Wexler D, Sheps D et al (2008) Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr Med Assoc J 10:884–888PubMed

64.

Honold J, Geiger L, Assmus B, Fischer-Rasokat U, Schaechinger V, Zeiher AM et al (2008) The initial slope of the VCO2/VO2-curve (s1) in cardiopulmonary exercise testing is a strong and independent predictor of outcome in patients with previous myocardial infarction. Clin Res Cardiol 97:882–890. doi:10.1007/s00392-008-701-6 PubMed

65.

Tsutamoto T, Nishiyama K, Sakai H, Tanaka T, Fujii M, Yamamoto T et al (2008) Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure. Eur J Heart Fail 10:1208–1214. doi:10.1016/j.ejheart.2008.09.011 PubMed

66.

Hinderliter AL, Blumenthal JA, O’Conner C, Adams KF, Dupree CS, Waugh RA et al (2008) Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure. Am Heart J 156:1191–1195. doi:10.1016/j.ahj.2008.07.022 PubMedCentralPubMed

67.

Frankenstein L, Remppis A, Nelles M, Schaelling B, Schellberg D, Katus H et al (2008) Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J 29:2634–2640. doi:10.1093/eurheartj/ehn388 PubMed

68.

Kallistratos MS, Dritsas A, Laoutaris ID, Cokkinos DV (2008) Incremental value of N-terminal pro-brain natriuretic peptide over left ventricle ejection fraction and aerobic capacity for estimating prognosis in heart failure patients. J Heart Lung Transplant 27:1251–1256. doi:10.1016/j.healun.2008.07.030 PubMed

69.

Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T et al (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003. doi:10.1016/j.jacc.2008.04.069 PubMed

70.

Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K et al (2008) Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 102:733–737. doi:10.1016/j.amjcard.2008.04.048 PubMed

71.

Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R (2008) Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 102:469–474. doi:10.1016/j.amjcard.2008.03.082 PubMed

72.

Dini FL, Fontanive P, Panicucci E, Andreini D, Chella P, De Tommasi SM (2008) Prognostic significance of tricuspid annular motion and plasma NT-proBNP in patients with heart failure and moderate-to-severe functional mitral regurgitation. Eur J Heart Fail 10:573–580. doi:10.1016/j.ejheart.2008.04.003 PubMed

73.

Amir O, Paz H, Ammar R, Yaniv N, Schliamser JE, and Lewis BS (2008) Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center. Isr Med Assoc J 10:109–12. http://www.ima.org.il/IMAJ/ViewArticle.aspx?year=2008&month=02&page=109

74.

Pascual-Figal DA, Domingo M, Casas T, Gich I, Ordóñnez-Llanos J, Martinez P et al (2008) Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 29:1011–1018. doi:10.1093/eurheartj/ehn023 PubMed

75.

Moertl D, Hammer A, Huelsmann M, Pacher R, Berger R (2008) Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients. Eur J Heart Fail 10:404–411. doi:10.1016/j.ejheart.2008.02.018 PubMed

76.

Koç M, Bozkurt A, Acarturk E, Sahin DY, Unal I (2008) Usefulness of N-terminal pro-B-type natriuretic peptide increase with exercise for predicting cardiovascular mortality in patients with heart failure. Am J Cardiol 101:1157–1162. doi:10.1016/j.amjcard.2007.11.070 PubMed

77.

Pfister R, Diedrichs H, Schiedermair A, Rosenkranz S, Hellmich M, Erdmann E et al (2008) Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 10:315–320. doi:10.1016/j.ejheart.2008.01.009 PubMed

78.

Gardner RS, Chong KS, O’Meara E, Jardine A, Ford I, McDonagh TA (2007) Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Heart J 28:3027–3033. doi:10.1093/eurheartj/ehm480 PubMed

79.

Tsutamoto T, Sakai H, Nishiyama K, Tanaka T, Fujii M, Yamamoto T et al (2007) Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J 71:1873–1878. doi:10.1253/circj.71.1873 PubMed

80.

von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P et al (2007) Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 50:1973–1980. doi:10.1016/j.jacc.2007.08.012

81.

Schou M, Gustafsson F, Kistorp CN, Corell P, Kjaer A, Hildebrandt PR (2007) Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure. Am J Cardiol 100:1571–1576. doi:10.1016/j.amjcard.2007.06.064 PubMed

82.

Frankenstein L, Nelles M, Slavutsky M, Schellberg D, Doesch A, Katus H et al (2007) Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. J Heart Lung Transplant 26:1033–1039. doi:10.1007/s00392-011-0340-1 PubMed

83.

Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W et al (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054–1060. doi:10.1016/j.jacc.2007.04.091 PubMed

84.

Michowitz Y, Goldstein E, Wexler D, Sheps D, Keren G, George J (2007) Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure. Heart 93:1046–1050. doi:10.1136/hrt.2006.102657 PubMedCentralPubMed

85.

Bayes-Genis A, Vazquez R, Puig T, Fernandez-Palomeque C, Fabregat J, Bardaji A et al (2007) Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. Eur J Heart Fail 9:802–807. doi:10.1016/j.ejheart.2007.05.001 PubMed

86.

Yin WH, Chen JW, Feng AN, Lin SJ, Young S (2007) Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin Cardiol 30:397–402. doi:10.1002/clc.20171 PubMed

87.

Petretta M, Colao A, Sardu C, Scopacasa F, Marzullo P, Pivonello R et al (2007) NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 17:288–296. doi:10.1016/j.ghir.2007.01.020 PubMed

88.

Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T et al (2007) Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28:1723–1730. doi:10.1093/eurheartj/ehm154 PubMed

89.

MacGowan GA, Neely D, Peaston R, Wrightson N, Parry G (2010) Evaluation of NT-proBNP to predict outcomes in advanced heart failure. Int J Clin Prac 64:892–899. doi:10.1111/j.1742-1241.2010.02388.x

90.

Song EK, Moser DK, Frazier SK, Heo S, Chung ML, Lennie TA (2010) Depressive symptoms affect the relationship of N-terminal pro B-type natriuretic peptide to cardiac event-free survival in patients with heart failure. J Card Fail 16:572–578. doi:10.1016/j.cardfail.2010.01.006 PubMedCentralPubMed

91.

Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880. doi:10.1093/eurheartj/ehq158 PubMed

92.

Jankowska EA, Filippatos GS, von Haehling S, Papassotiriou J, Morgenthaler NG, Cicoira M et al (2011) Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS One 6:e14506. doi:10.1371/journal.pone.0014506 PubMedCentralPubMed

93.

Tang WH, Shrestha K, Troughton RW, Borowski AG, Klein AL (2011) Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest Heart Fail 17:105–109. doi:10.1111/j.1751-7133.2011.00221.x PubMed

94.

Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L (2011) Parathyroid hormone and vitamin D-Markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 13:626–632. doi:10.1093/eurjhf/hfr016 PubMed

95.

Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Moure-González M, Seoane-Blanco A, Varela-Román A et al (2011) Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am J Cardiol 107:938–944. doi:10.1016/j.amjcard.2010.11.011 PubMed

96.

von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W et al (2010) Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 12:484–491. doi:10.1093/eurjhf/hfq031

97.

Van Den Broek KC, deFilippi CR, Christenson RH, Seliger SL, Gottdiener JS, Kop WJ (2011) Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality. Am J Cardiol 107:723–729. doi:10.1016/j.amjcard.2010.10.055 PubMedCentralPubMed

98.

Kawahara C, Tsutamoto T, Sakai H, Nishlyama K, Yamaji M, Fujii M et al (2011) Prognostic value of serial measurements of highly sensitive cardiac troponin i in stable outpatients with nonischemic chronic heart failure. Am Heart J 162:639–645. doi:10.1016/j.ahj.2011.07.007 PubMed

99.

Pfister R, Müller-Ehmsen J, Hagemeister J, Hellmich M, Erdmann E, Schneider CA (2011) NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure. Intern Med J 41:467–472. doi:10.1111/j.1445-5994.2010.02203.x PubMed

100.

Frankenstein L, Goode K, Ingle L, Remppis A, Schellberg D, Nelles M et al (2011) Derivation and validation of a simple clinical risk-model in heart failure based on 6 minute walk test performance and NT-proBNP status—do we need specificity for sex and beta-blockers? Int J Cardiol 147:74–78. doi:10.1016/j.ijcard.2009.08.005 PubMed

101.

Bajraktari G, Dini FL, Fontanive P, Elezi S, Berisha V, Napoli AM et al (2011) Independent and incremental prognostic value of Doppler-derived left ventricular total isovolumic time in patients with systolic heart failure. Int J Cardiol 148:271–275. doi:10.1016/j.ijcard.2009.09.567 PubMed

102.

Carlsen CM, Bay M, Kirk V, Gøtze JP, Køber L, Nielsen OW (2012) Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. Eur J Heart Fail 14:240–247. doi:10.1093/eurjhf/hfs003 PubMed

103.

Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P et al (2012) Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 14:268–277. doi:10.1093/eurjhf/hfs006 PubMed

104.

Tziakas DN, Chalikias GK, Stakos D, Chatzikyriakou SV, Papazoglou D, Mitrousi K et al (2012) Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Eur J Prev Cardiol 19:62–71. doi:10.1097/HJR.0b013e32833ace76 PubMed

105.

Bayes-Genis A, de Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R et al (2012) Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 14:32–38. doi:10.1093/eurjhf/hfr156 PubMed

106.

Franke J, Frankenstein L, Schellberg D, Bajrovic A, Wolter JS, Ehlermann P et al (2011) Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy? Clin Res Cardiol 100:1059–1067. doi:10.1007/s00392-011-0340-1 PubMed

107.

Jungbauer CG, Riedlinger J, Buchner S, Birner C, Resch M, Lubnow M et al (2011) High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-b-type natriuretic peptide. Clin Chem Lab Med 49:1899–1906. doi:10.1515/CCLM.2011.251 PubMed

108.

Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H et al (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4:569–577. doi:10.1161/CIRCHEARTFAILURE.111.962654 PubMed

109.

de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A (2012) Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J 163:821–828. doi:10.1016/j.ahj.2012.03.004 PubMed

110.

Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, Goetze JP et al (2012) Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail 18:351–358. doi:10.1016/j.cardfail.2012.01.019 PubMed

111.

Al-Najjar Y, Witte KK, Clark AL (2012) Chronotropic incompetence and survival in chronic heart failure. Int J Cardiol 157:48–52. doi:10.1016/j.ijcard.2010.11.018 PubMed

112.

Christensen HM, Frystyk J, Faber J, Schou M, Flyvbjerg A, Hildebrandt P et al (2012) a-Defensins and outcome in patients with chronic heart failure. Eur J Heart Fail 14:387–394. doi:10.1093/eurjhf/hfs021 PubMed

113.

Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC et al (2004) Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43:1590–1595. doi:10.1016/j.jacc.2003.10.066 PubMed

Title: BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure
Authors: Mark Oremus
Andrew Don-Wauchope
Robert McKelvie
Pasqualina L. Santaguida
Stephen Hill
Cynthia Balion
Ronald Booth
Judy A. Brown
Usman Ali
Amy Bustamam
Nazmul Sohel
Parminder Raina
Publication date: 01-08-2014
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 4/2014
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-014-9439-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Erratum to: Conflict of interest declaration

B-type natriuretic peptide-guided therapy: a systematic review

Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review

BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review

Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence

Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page